Onco-Innovations Weaves Preclinical Science and Pharma AI Deals as Stock Jumps 79%

Micro-cap biotech Onco-Innovations lands Big Pharma AI collaborations with AstraZeneca and GSK, advances PNKP inhibitor toward 2026 Phase 1 trial, and eyes Nasdaq listing.

A biotech with no revenues and a market cap of just €42.6 million rarely lands collaborations with AstraZeneca and GlaxoSmithKline. Onco-Innovations has done exactly that, pairing its early-stage drug development with an artificial intelligence subsidiary that is already attracting Big Pharma interest. The stock has surged 79% in the past 30 days to €0.70, but with a 52-week high of €1.49 still far ahead and annualised volatility above 133%, the ride remains anything but smooth.

Drug Pipeline Edges Toward the Clinic

On the therapeutic side, the company is pushing its PNKP inhibitor ONC010 (compound A83B4C63) through the final steps of preclinical preparation. In May, Onco-Innovations kicked off analytical method validation for the active pharmaceutical ingredient, working with Dalton Pharma Services to establish assays for purity and solvent residues in line with ICH guidelines. That follows the scale-up of two key intermediates reported in late April — necessary building blocks for reproducible manufacturing.

Parallel to that work, contract research organisation Nucro-Technics is collecting pharmacokinetic and biodistribution data from animal models. Those results are essential before toxicology studies can begin, and they will form the backbone of the investigational new drug application.

Avance Clinical, another partner, is preparing a meeting with the US Food and Drug Administration to align on trial design. Onco-Innovations plans to launch its first-in-human Phase 1 study in Australia in 2026, where it can claim a research and development tax credit that refunds up to 43.5% of eligible costs. “Validated analytical methods are a critical foundation for every step of clinical development,” said CEO Thomas O’Shaughnessy.

AI Unit Attracts Pharma Heavyweights

While the drug pipeline advances at a measured pace, the company’s subsidiary Inka Health is already generating commercial momentum. A new programme with AstraZeneca uses causal artificial intelligence to predict how well cancer therapies will work in individual patients. A separate agreement with GlaxoSmithKline tasks Inka Health with mining real-world clinical data to improve how trial results translate to broader patient populations.

The data feeding these AI models comes from a partnership with OneMedNet, which provides access to US oncology datasets. Palantir’s technology platform supports the analytics infrastructure. For Onco-Innovations, the deals serve a dual purpose: they bring in potential revenue and validate the subsidiary’s capabilities, while the parent company’s core drug programme remains years from generating its own sales.

Nasdaq Ambitions and a Thin Balance Sheet

On the capital markets front, management is preparing a secondary listing on the Nasdaq. An American investment banker is shepherding the process, and the company filed a preliminary base prospectus in Canada in February 2026 that would permit future capital raises. Regulatory approval is still pending.

The stock currently trades 19% below its level at the start of the year and 34% above its 50-day moving average — a telltale sign of the violent swings typical of a pre-revenue biotech. With no product sales and a market capitalisation that barely registers in the sector, Onco-Innovations must deliver on both its laboratory milestones and its AI tie-ups to justify the rally. The Nucro-Technics data, the FDA meeting, and the Nasdaq listing are the three near-term catalysts that will determine whether the 79% gain is a prelude to something bigger or another flash in the pan.